IL4 and gastric cancer: Co-presence of the above two markers, however, drastically multiplied the odds ratio and placed double-positive (HP-NAP-seropositive/-590T carrier) subjects at more than 30 fold (OR=33.64, 95% CI=2.06-548.68) increased risk of gastric cancer, as compared to double-negative (HP-NAP seronegative/IL-4 -590 CC) subjects (Fig. 2B).